Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Olympic flame in Rome: IOC President praises Italys warmth and energy
06 December 2025 - When the flame for the Milano Cortina 2026 Olympic Winter Games…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm…
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of…
Yidan Prize Foundation connects global insights and local expertise at annual flagship Summit
500 changemakers from over 50 countries stand in solidarity with Hong Kong…
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
ABU DHABI, Dec. 6, 2025 /PRNewswire/ -- The Abu Dhabi economic delegation,…
Rocket Doctor Announces Granting of RSUs and Options and a Change of CFO
December 05, 2025 17:00 ET | Source: Rocket Doctor AI Inc. Vancouver,…
Godrej Industries Group’s Assistive Tech Conference promotes accessible and equitable workplaces in India
MUMBAI, India, Dec. 6, 2025 /PRNewswire/ -- Godrej Industries Group recently hosted…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L…
